NCT00711880已完成3 期
A Double Blind, Randomised, Placebo Controlled Parallel Group Study of Cannabis Based Medicine Extract (CBME), in the Treatment of Peripheral Neuropathic Pain Characterised by Allodynia.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 125
- 试验地点
- 1
- 主要终点
- Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.
详细描述
This was a six week, multicentre, double blind, randomised, placebo controlled parallel group study to evaluate the efficacy of Sativex®. Subjects with peripheral neuropathic pain characterised by allodynia, were screened to determine eligibility and entered a seven day baseline period. Subjects then returned to the centre for randomisation and dose introduction, and received either placebo or Sativex in a double blind manner for five weeks, with a follow up visit 7 to 10 days after the end of the treatment period. The primary efficacy measure was the difference in pain severity at the end of treatment, measured using a peripheral neuropathic pain 0 to 10 numerical rating scale.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to give informed consent.
- •Male or female, aged 18 years or above.
- •Chronic peripheral neuropathic pain of at least six months duration.
- •Presence of mechanical allodynia within the territory of the affected nerve(s).
- •Evidence of sensory change in the affected nerve by simple clinical tests.
- •Peripheral neuropathic pain with a severity score of four or more on at least four completed NRS during the baseline week.
- •Stable dose of analgesic medication for at least two weeks leading to study entry.
- •Agreement, if female and of child bearing potential or if male with a partner of child bearing potential, to ensure that effective contraception was used during the study and for three months thereafter.
- •Have not used cannabinoids (including cannabis, Marinol or Nabilone) for at least seven days before Visit 1 and were willing to abstain from any use of cannabinoids during the study.
- •Ability (in the investigator's opinion) and willingness to comply with all study requirements.
- •Agreement for the UK Home Office, their primary care physician, and their consultant if appropriate, to be notified of their participation in the study.
排除标准
- •History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
- •Concomitant severe non-neuropathic pain or the presence of cancer related neuropathic pain or neuropathic pain resulting from diabetes mellitus.
- •Known history of alcohol or substance abuse.
- •Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure.
- •History of epilepsy.
- •If female, were pregnant or lactating, or were planning a pregnancy to occur during the course of the study.
- •Significant renal or hepatic impairment.
- •Elective surgery or other procedures requiring general anaesthesia scheduled to occur during the study.
- •Terminal illness or were considered inappropriate for placebo medication.
- •Any other significant disease or disorder which, in the opinion of the investigator, may have either put the subject at risk because of participation in the study, or may influenced the result of the study, or the subject's ability to participate in the study.
- •Regular levodopa (Sinemet®, Sinement Plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®) therapy within the seven days leading to study entry.
- •If male, were receiving and were unwilling to stop sildenafil (Viagra®) for the duration of the study.
- •Known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medications.
- •Known or suspected adverse reaction to cannabinoids.
- •Intention to travel internationally during the study.
- •Intention to donate blood during the study.
- •Participation in another research study in the 12 weeks leading to study entry.
- •Previous randomisation into this study
研究组 & 干预措施
Sativex
Experimental
干预措施: Sativex® (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)
时间窗: Day 0 to Day 42
The neuropathic pain Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = worst possible pain. A negative value indicates an improvement in pain score from baseline.
次要结局
- Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment(Day 7 and Day 42)
- Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment(Day 7 and Day 42)
- Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment(Day 7 and Day 42)
- Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment(Day 0 to Day 42)
- Change From Baseline in Mean Sleep Quality at the End of Treatment(Day 7 - Day 42)
- Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment(Day 0 - Day 42)
- Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment(Day 0 - Day 42)
- Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment(Day 7 and Day 42)
- Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment(Day 7 and Day 42)
- Subject Global Impression of Change in the Severity of Allodynia in Their Chosen Allodynic Area at the End of Treatment(Day 0 - 42)
- Incidence of Adverse Events as a Measure of Subject Safety(Day 0 - Day 42)
- Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment(Day 7 and Day 42)
- Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment(Day 7 and Day 42)
- Subject Global Impression of Change in the Severity of Peripheral Neuropathic Pain at the End of Treatment(Day 42)
- Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment(Day 0 - Day 42)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of Sativex® for Pain Relief Due to Diabetic NeuropathyPainDiabetic NeuropathyNCT00710424Jazz Pharmaceuticals297
已完成
3 期
A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With AllodyniaPainPeripheral NeuropathyNCT00710554Jazz Pharmaceuticals246
已完成
3 期
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple SclerosisDetrusor OveractivityMultiple SclerosisNCT00678795Jazz Pharmaceuticals135
已完成
3 期
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple SclerosisMultiple SclerosisNCT01599234Jazz Pharmaceuticals337
已完成
3 期
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.SpasticityMultiple SclerosisNCT00711646Jazz Pharmaceuticals189